BOEHRINGER-INGELHEIM
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center.
“The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.”
The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning in 2020, the new building will be home to 500 employees. This is an increase of about 100 employees in biologicals development compared to today.
The new BDC adds to a number of major recent investments into the global Boehringer Ingelheim biopharmaceuticals development network aiming to further increase the company’s mammalian cell culture capabilities in this important area, including the large scale biopharmaceuticals facility in Vienna, Austria, a new biopharmaceuticals facility in Shanghai, China, and the expansion of existing large scale biopharmaceutical capacities in Fremont, CA, USA, leading to an overall increase of investment in biopharmaceutical research, development and production.
Boehringer Ingelheim has developed biopharmaceuticals, such as a humanized antibody fragment that selectively reverts the effect of an oral anticoagulant prior to urgent procedures / emergency surgery or in uncontrolled bleeding, a first-in-class Interleukin-36 receptor antibody is being tested among others for special forms of psoriasis (generalized pustular psoriasis and palmoplantar pustulosis) as well as ulcerative colitis and crohn’s disease and several antibodies under investigation for difficult to treat cancers. Boehringer Ingelheim is committing more than 20% of its human pharma net sales to Research & Development. More than 8,000 employees work in four R&D centers of excellence on a highly innovative pipeline, 50% of which is anchored in external innovation.
Boehringer Ingelheim BioXcellence™ is a leader in biopharmaceutical contract manufacturing for large volume products, manufacturing 29 biopharmaceuticals for industry partners from around the world. These include monoclonal antibodies for oncology and immunology, interferons and other targeted therapies.
~ENDS~
Please click on the link for ‘Notes to Editors’:http://www.boehringer-ingelheim.com/press-release/new-biologicals-development-center-germany-announced
View source version on businesswire.com: https://www.businesswire.com/news/home/20180622005245/en/
Contact:
Boehringer Ingelheim
Matthias Reinig
Corporate Topics
Boehringer
Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 184855
press@boehringer-ingelheim.com
or
Boehringer
Ingelheim
Dr. Reinhard Malin
Innovation Unit
Boehringer
Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
press@boehringer-ingelheim.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OH-FORGE-BIOLOGICS19.3.2024 13:01:30 CET | Press release
Forge Biologics’ Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is Granted UK’s Innovation Passport Designation
MAINSTAY-MEDICAL19.3.2024 13:01:29 CET | Press release
Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up
SWISSTO1219.3.2024 13:01:29 CET | Press release
SWISSto12 Continues Expansion, Growing Team by 25% and Adding New Production Space
CO-ANGLOGOLD-ASHANTI-PLC19.3.2024 12:05:35 CET | Press release
AngloGold Ashanti Releases Preliminary Unaudited Condensed Consolidated Financial Statements as of and for the Six Months and the Year Ended 31 December 2023
NY-IFF19.3.2024 11:46:34 CET | Press release
IFF Announces Sale of its Pharma Solutions Business to Roquette
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom